Esther Rajavelu, CFO & CBO at Spero Therapeutics, Inc. (SPRO), sold 40,596 shares at $1.30 ($53K) on 2024-11-08, disclosed to the SEC on 2024-11-12.
Open-market sale of $53k SPRO by CFO & CBO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.31 | 23,351 | $31K | 57.7% |
| 2 | $1.30 | 17,245 | $22K | 42.3% |
| Total | $1.31 avg | 40,596 | $53K | 100% |
| Filing → |
| SPRO | SELL | 2026-02-04 | $41K | — | Filing → |
| SPRO | SELL | 2025-11-12 | $191K | — | Filing → |
| SPRO | SELL | 2025-02-05 | $16K | — | Filing → |